ロード中...
Preclinical in vivo validation of the RAD51 test for identification of homologous recombination-deficient tumors and patient stratification
PARP inhibitors (PARPi) are approved drugs for platinum-sensitive, high-grade serous ovarian cancer (HGSOC) and for breast (BC), prostate, and pancreatic cancers (PaC) harboring genetic alterations impairing homologous recombination repair (HRR). Detection of nuclear RAD51 foci in tumor cells is a m...
保存先:
| 出版年: | Cancer Res |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2022
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7612637/ https://ncbi.nlm.nih.gov/pubmed/35425960 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-21-2409 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|